BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

683 related articles for article (PubMed ID: 35414102)

  • 1. Growth factor independence underpins a paroxysmal, aggressive Wnt5a
    Trivieri N; Visioli A; Mencarelli G; Cariglia MG; Marongiu L; Pracella R; Giani F; Soriano AA; Barile C; Cajola L; Copetti M; Palumbo O; Legnani F; DiMeco F; Gorgoglione L; Vescovi AL; Binda E
    J Exp Clin Cancer Res; 2022 Apr; 41(1):139. PubMed ID: 35414102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different states of stemness of glioblastoma stem cells sustain glioblastoma subtypes indicating novel clinical biomarkers and high-efficacy customized therapies.
    Visioli A; Trivieri N; Mencarelli G; Giani F; Copetti M; Palumbo O; Pracella R; Cariglia MG; Barile C; Mischitelli L; Soriano AA; Palumbo P; Legnani F; DiMeco F; Gorgoglione L; Pesole G; Vescovi AL; Binda E
    J Exp Clin Cancer Res; 2023 Sep; 42(1):244. PubMed ID: 37735434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NSG-70, a new glioblastoma cell line with mixed proneural-mesenchymal features, associates NOTCH1-WNT5A signaling with stem cell maintenance and angiogenesis.
    Singh DK; Shivalingappa PKM; Sharma A; Mondal A; Muzumdar D; Shiras A; Bapat SA
    J Neurooncol; 2022 May; 157(3):575-591. PubMed ID: 35430703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High expression of RFX4 is associated with tumor progression and poor prognosis in patients with glioblastoma.
    Jeong HY; Kim HJ; Kim CE; Lee S; Choi MC; Kim SH
    Int J Neurosci; 2021 Jan; 131(1):7-14. PubMed ID: 32075484
    [No Abstract]   [Full Text] [Related]  

  • 5. Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells.
    Wakimoto H; Mohapatra G; Kanai R; Curry WT; Yip S; Nitta M; Patel AP; Barnard ZR; Stemmer-Rachamimov AO; Louis DN; Martuza RL; Rabkin SD
    Neuro Oncol; 2012 Feb; 14(2):132-44. PubMed ID: 22067563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mir-370-3p Impairs Glioblastoma Stem-Like Cell Malignancy Regulating a Complex Interplay between HMGA2/HIF1A and the Oncogenic Long Non-Coding RNA (lncRNA) NEAT1.
    Lulli V; Buccarelli M; Ilari R; Castellani G; De Dominicis C; Di Giamberardino A; D Alessandris QG; Giannetti S; Martini M; Stumpo V; Boe A; De Luca G; Biffoni M; Marziali G; Pallini R; Ricci-Vitiani L
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32443824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-129-5p targets Wnt5a to block PKC/ERK/NF-κB and JNK pathways in glioblastoma.
    Zeng A; Yin J; Li Y; Li R; Wang Z; Zhou X; Jin X; Shen F; Yan W; You Y
    Cell Death Dis; 2018 Mar; 9(3):394. PubMed ID: 29531296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
    Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
    Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated invasive potential of glioblastoma stem cells.
    Cheng L; Wu Q; Guryanova OA; Huang Z; Huang Q; Rich JN; Bao S
    Biochem Biophys Res Commun; 2011 Mar; 406(4):643-8. PubMed ID: 21371437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EphA2 promotes infiltrative invasion of glioma stem cells in vivo through cross-talk with Akt and regulates stem cell properties.
    Miao H; Gale NW; Guo H; Qian J; Petty A; Kaspar J; Murphy AJ; Valenzuela DM; Yancopoulos G; Hambardzumyan D; Lathia JD; Rich JN; Lee J; Wang B
    Oncogene; 2015 Jan; 34(5):558-67. PubMed ID: 24488013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The LIM-only transcription factor LMO2 determines tumorigenic and angiogenic traits in glioma stem cells.
    Kim SH; Kim EJ; Hitomi M; Oh SY; Jin X; Jeon HM; Beck S; Jin X; Kim JK; Park CG; Chang SY; Yin J; Kim T; Jeon YJ; Song J; Lim YC; Lathia JD; Nakano I; Kim H
    Cell Death Differ; 2015 Sep; 22(9):1517-25. PubMed ID: 25721045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting role of glioma stem cells for glioblastoma multiforme.
    Zhang X; Zhang W; Mao XG; Zhen HN; Cao WD; Hu SJ
    Curr Med Chem; 2013; 20(15):1974-84. PubMed ID: 23317162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of EGFR induces a c-MET-driven stem cell population in glioblastoma.
    Jun HJ; Bronson RT; Charest A
    Stem Cells; 2014 Feb; 32(2):338-48. PubMed ID: 24115218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth.
    Zhou W; Cheng L; Shi Y; Ke SQ; Huang Z; Fang X; Chu CW; Xie Q; Bian XW; Rich JN; Bao S
    Oncotarget; 2015 Nov; 6(35):37300-15. PubMed ID: 26510911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wnt/β-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells.
    Kim KH; Seol HJ; Kim EH; Rheey J; Jin HJ; Lee Y; Joo KM; Lee J; Nam DH
    Neuro Oncol; 2013 Feb; 15(2):161-71. PubMed ID: 23258844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
    Signore M; Pelacchi F; di Martino S; Runci D; Biffoni M; Giannetti S; Morgante L; De Majo M; Petricoin EF; Stancato L; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L
    Cell Death Dis; 2014 May; 5(5):e1223. PubMed ID: 24810059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations.
    Garner JM; Ellison DW; Finkelstein D; Ganguly D; Du Z; Sims M; Yang CH; Interiano RB; Davidoff AM; Pfeffer LM
    PLoS One; 2015; 10(5):e0125838. PubMed ID: 25955030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic Activation of WNT5A Drives Glioblastoma Stem Cell Differentiation and Invasive Growth.
    Hu B; Wang Q; Wang YA; Hua S; Sauvé CG; Ong D; Lan ZD; Chang Q; Ho YW; Monasterio MM; Lu X; Zhong Y; Zhang J; Deng P; Tan Z; Wang G; Liao WT; Corley LJ; Yan H; Zhang J; You Y; Liu N; Cai L; Finocchiaro G; Phillips JJ; Berger MS; Spring DJ; Hu J; Sulman EP; Fuller GN; Chin L; Verhaak RGW; DePinho RA
    Cell; 2016 Nov; 167(5):1281-1295.e18. PubMed ID: 27863244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cotargeting Ephrin Receptor Tyrosine Kinases A2 and A3 in Cancer Stem Cells Reduces Growth of Recurrent Glioblastoma.
    Qazi MA; Vora P; Venugopal C; Adams J; Singh M; Hu A; Gorelik M; Subapanditha MK; Savage N; Yang J; Chokshi C; London M; Gont A; Bobrowski D; Grinshtein N; Brown KR; Murty NK; Nilvebrant J; Kaplan D; Moffat J; Sidhu S; Singh SK
    Cancer Res; 2018 Sep; 78(17):5023-5037. PubMed ID: 29945963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome-wide methylomic and transcriptomic analyses identify subtype-specific epigenetic signatures commonly dysregulated in glioma stem cells and glioblastoma.
    Pangeni RP; Zhang Z; Alvarez AA; Wan X; Sastry N; Lu S; Shi T; Huang T; Lei CX; James CD; Kessler JA; Brennan CW; Nakano I; Lu X; Hu B; Zhang W; Cheng SY
    Epigenetics; 2018; 13(4):432-448. PubMed ID: 29927689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.